Acrivon Advances ACR-2316 Into Randomized Dose Expansion
Acrivon starts dose expansion in phase 1/2 study
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Acrivon starts dose expansion in phase 1/2 study
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.